Spots Global Cancer Trial Database for Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
Official Title: A PHASE 1B, MULTI-CENTER, OPEN-LABEL STUDY OF THE MTOR KINASE INHIBITOR CC-223 IN COMBINATION WITH ERLOTINIB OR ORAL AZACITIDINE IN ADVANCED NON-SMALL CELL LUNG CANCER
Study ID: NCT01545947
Study Description
Brief Summary: The main purpose of this first study combining an investigational dual mTOR inhibitor, CC-223, with other agents (erlotinib or the investigational agent, oral azacitidine) is to establish a maximum tolerated dose level for each combination in order to evaluate their effects in future clinical trials for advanced non-small cell lung cancer.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Cedars Sinai Medical Center, Inflammatory Bowel Disease Center, Los Angeles, California, United States
University of California, San Francisco, San Francisco, California, United States
NYU School of Medicine, New York, New York, United States
Cancer Center of the Carolinas, Greenville, South Carolina, United States
Henry-Joyce Cancer Clinic, Nashville, Tennessee, United States
Mary Crowley Cancer Research Centers - Medical City, Dallas, Texas, United States
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Vall d´Hebron University Hospital, Barcelona, , Spain
Hospital Virgen del Rocio Servicio de Hematologia, Sevilla, , Spain
Contact Details
Name: Kristen Hege, MD
Affiliation: Celgene Corporation
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
